2021
A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.
Verma R, Patil S, Zhang N, Moreira F, Vitorio M, Santos A, Wallace E, Gnanashanmugam D, Persing D, Savic R, Croda J, Andrews J. A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment. American Journal Of Respiratory And Critical Care Medicine 2021, 204: 1317-1326. PMID: 34375564, DOI: 10.1164/rccm.202103-0564oc.Peer-Reviewed Original ResearchConceptsPharmacogenomic assaysSparse pharmacokinetic samplingInadequate treatment responseInterindividual pharmacokinetic variabilityAcetylation genotypeIsoniazid clearancePharmacokinetic samplingPulmonary tuberculosisWhole blood samplesIntermediate acetylatorsPharmacokinetic variabilityFast acetylatorsNAT2 polymorphismsAcetylator typeSlow acetylatorsTuberculosis treatmentTreatment responseBlood samplesGeneXpert platformTuberculosis diagnosisVariable drug concentrationsHealthy individualsPersonalized dosingSubstantial incidenceStandardized dosing
2013
Genetic polymorphism and immune response to tuberculosis in indigenous populations: a brief review
Longhi R, Zembrzuski V, Basta P, Croda J. Genetic polymorphism and immune response to tuberculosis in indigenous populations: a brief review. The Brazilian Journal Of Infectious Diseases 2013, 17: 363-368. PMID: 23665009, PMCID: PMC9427389, DOI: 10.1016/j.bjid.2012.11.001.Peer-Reviewed Original ResearchMeSH KeywordsCytokinesHumansImmunity, HumoralPolymorphism, GeneticPopulation GroupsTh1 CellsTh2 CellsTuberculosisConceptsImmune responseCytokine expressionGenetic polymorphismsHigher IL-5 productionTh2-type responseIL-5 productionTuberculin skin testIFN-γ productionRelevant genetic polymorphismsActive diseaseTB infectionCytokine levelsLower TNFHigh IgG4IgM levelsIL-12p40Skin testImmunogenetic mechanismsImmune regulationInclusion criteriaNew treatmentsMajority of studiesTuberculosisSearch termsIndigenous populations